Role of Platelet Mass Index in the Differential Diagnosis of Patients with Elevated Prostate-Specific Antigen Levels

Abstract

Aim: To evaluate the role of platelet mass index (PMI) calculated using hemogram parameters obtained from a routine blood test in the differentiation of prostate cancer in patients with prostate-specific antigen (PSA) values of 2.5-10 ng/dl. Material and Method: Seventy-five patients with prostate cancer and 48 with prostatitis were included in the study and grouped according to their pathology results. The white blood cell (WBC), hemoglobin (HGB), thrombocyte (PLT), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), mean platelet volume (MPV) and PMI values were compared between the two groups. Results: The PMI and PLT levels of the prostate cancer group were statistically significantly lower than those of the prostatitis group (p<0.05). In predicting prostate cancer, the cut-off value for the PMI level was determined as 1.480, at which the likelihood ratio was calculated as 1.08. Conclusion: We consider that PMI calculated using hemogram parameters in patients with a PSA value below 10 ng/dl will guide the clinician in differentiating prostate cancer from other prostate pathologies without performing an unnecessary biopsy.